Forecast

The analysts' average price target is €130.24 (+0.88%). The median is €131.32 (+1.72%).

Buy	39
Hold	18
Sell	1

News Go to news feed

Gilead wins third FDA approval in under four months as pipeline boosts outlook

Gilead secured three FDA approvals in the past four months, most recently for Bixlenvo for virologically suppressed adults with HIV, adding to approvals for Trodelvy and Hepcludex. Near-term catalysts include PDUFA target dates for anito-cel (Dec. 23) and once-weekly oral Yeztugo for PrEP (Feb. 2), plus a planned 2027 launch of a weekly lenacapavir-islatravir combo. The company reported Q2 revenue of $7.6 billion (up 8% y/y), raised its quarterly dividend to $0.82, executed buybacks, and posted gross margins near 87%, supporting management’s case for durable cash generation despite HIV-related concentration risks. » More on finance.yahoo.com
Gilead Sciences gets FDA approval for once-daily HIV combination pill Bixlenvo

The U.S. FDA approved Gilead Sciences' once-daily oral combination pill Bixlenvo for adults whose HIV infection is already reduced to very low levels. Bixlenvo combines bictegravir, the core of Biktarvy, with capsid inhibitor lenacapavir, which is also marketed as Sunlenca and Yeztugo. The approval expands oral treatment options for virally suppressed patients. » More on yahoo.com
Gilead receives EU approval for Trodelvy in combination with Keytruda for triple-negative breast cancer

The European Commission has approved Trodelvy (sacituzumab govitecan) in combination with Keytruda (pembrolizumab) for adult women with inoperable or metastatic, PD‑L1‑positive (CPS≥10) triple‑negative breast cancer. The decision applies to the 27 EU member states as well as Norway, Iceland and Liechtenstein and is based on data from the phase‑III ASCENT‑04/KEYNOTE‑D19 study. The combination reduced the risk of disease progression or death by 35% versus standard chemotherapy plus Keytruda. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Gilead Sciences has already paid €1.44 in dividends. The last payout was in June.

Financials

In the last quarter, Gilead Sciences had revenue of €6.84B and net profit of -€9.2B

(EUR)	June 2026	YoY
Revenue	6.84B	13.81%
Gross profit	5.45B	15.19%
Net profit	-9.2B	653.05%
EBITDA	-8.77B	406.31%

Fundamentals

Metric	Value
Market capitalization	€161.43B
Number of shares	1.24B
52-week high/low	€135.44 - €93.40
Dividend yield	2.15%
Dividends TTM	€2.78
Next dividend	€0.70
Beta	0.35
P/E ratio	-58.08
PEG ratio	0.38
P/B ratio	15.87
P/S ratio	6.16

Company profile

Das biopharmazeutische Unternehmen Gilead Sciences, Inc. erforscht, entwickelt und vermarktet Medikamente in Bereichen mit ungedecktem medizinischem Bedarf in den Vereinigten Staaten, Europa und international. Das Unternehmen bietet die Produkte Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild und Atripla für die Behandlung von HIV/AIDS; Veklury, eine Injektion zur intravenösen Anwendung, für die Behandlung der Coronavirus-Krankheit 2019; und Epclusa, Harvoni, Vosevi, Vemlidy und Viread für die Behandlung von Lebererkrankungen. Es bietet auch Yescarta, Tecartus, Trodelvy und Zydelig Produkte für die Behandlung von Hämatologie, Onkologie und Zelltherapie Patienten. Darüber hinaus bietet das Unternehmen Letairis, eine orale Formulierung zur Behandlung der pulmonalen arteriellen Hypertonie, Ranexa, eine orale Formulierung zur Behandlung der chronischen Angina pectoris, und AmBisome, eine liposomale Formulierung zur Behandlung schwerer invasiver Pilzinfektionen. Gilead Sciences, Inc. hat Kooperationsvereinbarungen mit Arcus Biosciences, Inc; Pionyr Immunotherapeutics Inc; Tizona Therapeutics, Inc; Tango Therapeutics, Inc; Jounce Therapeutics, Inc; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc; und Merck & Co, Inc. Das Unternehmen wurde 1987 gegründet und hat seinen Hauptsitz in Foster City, Kalifornien.